APOLLOMICS
Apollomics is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including the novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
APOLLOMICS
Industry:
Biotechnology Health Care Oncology Pharmaceutical
Founded:
2016-01-01
Address:
Foster City, California, United States
Country:
United States
Website Url:
http://www.apollomicsinc.com
Total Employee:
11+
Status:
Active
Contact:
+1-650-209-4055
Total Funding:
262.6 M USD
Technology used in webpage:
SPF IPv6 Cloudflare Hosting Cloudflare DNS Intermedia
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
New Century Pharmaceuticals
New Century Pharmaceuticals, Inc. is a biopharmaceutical company with an Oncology and Anti-infective focus which uses leading expertise.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ping An Capital
Ping An Capital investment in Series C - Apollomics
WR Hambrecht
WR Hambrecht investment in Series C - Apollomics
CMB International Capital Corporation
CMB International Capital Corporation investment in Series B - Apollomics
Junson Capital
Junson Capital investment in Series B - Apollomics
Guangzhou Yue Min Investment
Guangzhou Yue Min Investment investment in Series B - Apollomics
OrbiMed
OrbiMed investment in Series B - Apollomics
K2VC
K2VC investment in Series B - Apollomics
South China Venture Capital
South China Venture Capital investment in Series B - Apollomics
Pan-Lin Capital
Pan-Lin Capital investment in Series B - Apollomics
OrbiMed
OrbiMed investment in Series A - Apollomics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-17 | MabPlex International | Apollomics investment in Series A - MabPlex International | 400 M CNY |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-04 | Apollomics appoints CFO |
Official Site Inspections
http://www.apollomicsinc.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.26 K
- Host name: 104.26.0.173
- IP address: 104.26.0.173
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Apollomics"
Our Company - Apollomics, Inc.
At Apollomics, we are a purpose-driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the …See details»
Management - Apollomics, Inc.
Dr. Guo Liang Yu is a co-founder, Executive Director, Chairman and Chief Executive Officer of Apollomics. Dr. Yu has been one of the key management members of the Company and has …See details»
Governance Overview - Apollomics, Inc.
The Board of Directors of Apollomics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Apollomics - LinkedIn
Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies.See details»
Release Details - ir.apollomicsinc.com
Jan 4, 2022 The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in …See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as …
Jan 4, 2022 The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. ...See details»
Investor FAQs - Apollomics, Inc.
For any questions regarding your holdings, please contact our transfer agent, Continental Stock Transfer & Trust Company, by calling 212.509.4000 or 800.509.5586 or emailing …See details»
Board of Directors - Apollomics, Inc.
In December 2022, Wendy completed a two-year fellowship in Advanced Leadership Initiative at Harvard University. Wendy also worked as an Inspections Leader and led inspections for the Public Company Accounting Oversight …See details»
Apollomics, Inc. (APLM) - Yahoo Finance
Find the latest Apollomics, Inc. (APLM) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Apollomics, a Company Developing Novel Oncology Therapies
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology …See details»
Apollomics to Present at the H.C. Wainwright 26th Annual Global ...
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing …See details»
Press Releases - Apollomics, Inc.
Nov 22, 2021 The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in …See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed
Jan 4, 2022 Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting …See details»
Apollomics Announces Updated Strategic Focus and Leadership …
Jul 3, 2024 Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical needFOSTER CITY, …See details»
Apollomics, Inc. Strengthens Leadership with Key Hires
Jan 16, 2019 Wilson W. Cheung, CPA appointed Chief Financial Officer Debra L. Thoma Vallner, PhD, MBA named Senior Vice President, Development Operations Foster City, CA, …See details»
Apollomics to Announce Full Year 2023 Financial Results and Host ...
FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address …See details»
Join Our Team - Apollomics, Inc.
We are committed to the well-being of our employees and offer medical, dental, and vision insurance. We offer competitive personal time off (PTO) days, a health club subsidy, and a …See details»
Our Approach - Apollomics, Inc.
Apollomics is committed to the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and …See details»
Apollomics Announces Presentation at the 2024 BIO International ...
FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple …See details»